<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Luminex Corp News Release</title><link>http://phx.corporate-ir.net/Phoenix.zhtml?c=79403&amp;p=irol-news</link><description>A Collection of Luminex Corp News Release</description><language>en-us</language><category>Uncategorized</category><lastBuildDate>Tue, 21 May 2013 02:08:05 GMT</lastBuildDate><item><title>Luminex Corporation To Present At Upcoming Investment Conferences</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1816637</link><description><![CDATA[AUSTIN, Texas, May 7, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at three upcoming investment conferences: 

The UBS Global Healthcare Conference on Tuesday, May 21 at 1pm ET in New York City

The Jefferies 2013 Global Healthcare Conference on Tuesday, June 4 at 1:30pm ET in New York City, and

The Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11 at 1:20pm PT in Rancho Palos Verdes   

The presentations will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investo...]]></description><category>Uncategorized</category><guid isPermaLink="false">1816637_NEWS</guid><pubDate>Tue, 07 May 2013 20:05:54 GMT</pubDate></item><item><title>Luminex Corporation Reports First Quarter 2013 Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1812552</link><description><![CDATA[GAINED FDA CLEARANCE FOR NOVEL GASTROINTESTINAL PATHOGEN PANEL


AUSTIN, Texas, April 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2013.  Financial and operating highlights include the following: 


Consolidated first quarter revenue was $53.2 million, a 9 percent increase over the first quarter of 2012 
Consolidated gross profit margin was 71 percent for the first quarter of 2013, compared to 69 percent for the first quarter of 2012 
Non-GAAP net income for the first quarter was $7.9 million or $0.19 per diluted share. This compares to non-GAAP net income of $6.6 million, or $0.15 per diluted share...]]></description><category>Uncategorized</category><guid isPermaLink="false">1812552_NEWS</guid><pubDate>Mon, 29 Apr 2013 20:05:52 GMT</pubDate></item><item><title>Luminex Corporation Receives U.S. FDA Clearance for MAGPIX® Instrument with Novel xTAG® Gastrointestinal Pathogen Panel</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1806620</link><description><![CDATA[Innovative multiplexing instrument for clinical laboratories with simultaneous testing for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test now available








 
 
AUSTIN, Texas, April 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical assay to be cleared on MAGPIX. xTAG GPP is the first U.S. IVD cleared test that can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample...]]></description><category>Uncategorized</category><guid isPermaLink="false">1806620_NEWS</guid><pubDate>Mon, 15 Apr 2013 12:31:04 GMT</pubDate></item><item><title>Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1804336</link><description><![CDATA[AUSTIN, Texas, April 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the first quarter of 2013 on Monday, April 29, 2013 after the close of trading. 

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013 on April 29, 2013, at 5:00 p.m. Eastern time. 

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the Ab...]]></description><category>Uncategorized</category><guid isPermaLink="false">1804336_NEWS</guid><pubDate>Mon, 08 Apr 2013 20:05:55 GMT</pubDate></item><item><title>Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1795234</link><description><![CDATA[Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease 
WHITEHOUSE STATION, N.J. &amp; AUSTIN, Texas--(BUSINESS WIRE)--Mar. 13, 2013-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). F...]]></description><category>Uncategorized</category><guid isPermaLink="false">1795234_NEWS</guid><pubDate>Wed, 13 Mar 2013 13:41:00 GMT</pubDate></item><item><title>Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1781152</link><description><![CDATA[

AUSTIN, Texas, Feb. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2012.  Financial and operating highlights include the following: 


Consolidated fourth quarter revenue of $55.5 million, a 16 percent increase over the fourth quarter of 2011; full-year 2012 revenue was $202.6 million, a 10 percent increase over 2011 
Fourth quarter assay revenue of $23.8 million, a 45 percent increase over the fourth quarter of 2011; full-year 2012 assay revenue was $75.0 million, a 54 percent increase over 2011 
Fourth quarter shipments of 226 multiplexing analyzers; cumulative life-to-date multiplexing...]]></description><category>Uncategorized</category><guid isPermaLink="false">1781152_NEWS</guid><pubDate>Mon, 04 Feb 2013 21:06:04 GMT</pubDate></item><item><title>Luminex Corporation To Present At Leerink Swann Global Healthcare Conference</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1780226</link><description><![CDATA[

AUSTIN, Texas, Jan. 31, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Leerink Swann Global Healthcare Conference to be held February 13 -14, 2013, in New York, NY.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) 

The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 11:30 a.m. Eastern time on Thursday, February 14, 2013.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Plea...]]></description><category>Uncategorized</category><guid isPermaLink="false">1780226_NEWS</guid><pubDate>Thu, 31 Jan 2013 21:07:09 GMT</pubDate></item><item><title>Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 4, 2013</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1775308</link><description><![CDATA[

AUSTIN, Texas, Jan. 16, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter of 2012 on Monday, February 4, 2013. A press release announcing the results is scheduled for release after the close of trading. 

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended December 31, 2012 on February 4, 2013, at 5:00 p.m. Eastern time. 

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex...]]></description><category>Uncategorized</category><guid isPermaLink="false">1775308_NEWS</guid><pubDate>Wed, 16 Jan 2013 21:05:16 GMT</pubDate></item><item><title>Luminex Receives FDA Clearance for First Comprehensive Gastrointestinal Pathogen Infectious Disease Diagnostic in the United States</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1774617</link><description><![CDATA[xTAG® Gastrointestinal Pathogen Panel (GPP) simultaneously tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.



 
 
 
 
AUSTIN, Texas, Jan. 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), the first comprehensive molecular diagnostic assay that tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay. The xTAG GPP assay can be an important clinical tool in the management of gastrointestinal infections, and is now available in the United ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1774617_NEWS</guid><pubDate>Tue, 15 Jan 2013 13:30:33 GMT</pubDate></item><item><title>Luminex Corporation To Present At JP Morgan Healthcare Conference</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=79403&amp;p=RssLanding&amp;cat=news&amp;id=1770588</link><description><![CDATA[

AUSTIN, Texas, Jan. 2, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 31st Annual JP Morgan Healthcare Conference to be held January 7 -10, 2013, in San Francisco, CA.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, January 9, 2013.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Inve...]]></description><category>Uncategorized</category><guid isPermaLink="false">1770588_NEWS</guid><pubDate>Wed, 02 Jan 2013 21:06:03 GMT</pubDate></item></channel></rss>